Skip to main content
Kevin Alexander, MD, Cardiology, Palo Alto, CA

KevinMichaelAlexanderMD

Cardiology Palo Alto, CA

Heart Failure & Transplantation

Physician

Dr. Alexander is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Alexander's full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Palo Alto, CA 94305
    Phone+1 205-541-7371

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Advanced Heart Failure and Transplant Cardiology, 2018 - 2019
  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2014 - 2017
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2011

Certifications & Licensure

  • HI State Medical License
    HI State Medical License 2022 - 2026
  • CA State Medical License
    CA State Medical License 2018 - 2025
  • MA State Medical License
    MA State Medical License 2015 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29th, 2024
  • BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
    BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingMay 25th, 2024
  • Additional Data Showing Acoramidis Increases Serum Transthyretin Which Is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Additional Data Showing Acoramidis Increases Serum Transthyretin Which Is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 30th, 2024